ACR Convergence 2025 Archives - Page 180 of 182

Abstract Number: 0482

R-2487, a Synthetic Biology-Based Oral Immunotherapy, Promotes Treg-Mediated Immune Rebalancing and Reduces Disease Activity in Rheumatoid Arthritis Patients
Abstract Number: 0066

RA-required synovial tissue-resident monocyte lineage cells are comprised of three distinct subpopulations.
Abstract Number: 1513

Race, Renal Failure, and Risk: A five-to-ten year retrospective cohort study of Racial differences in outcomes of patients with dialysis-dependent Lupus nephritis
Abstract Number: 0478

Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
Abstract Number: 1707

Racial and Ethnic Disparities in Kidney Transplant Outcomes Among Patients With Systemic Lupus Erythematosus (SLE): A 20-Year Analysis Spanning Before and After the 2014 Kidney Allocation System Revision
Abstract Number: 2230

Racial and Ethnic Disparities in Rheumatoid Arthritis-Associated Interstitial Lung Disease and Their Impact on Antifibrotic Therapy
Abstract Number: 1012

Racial and Gender Disparities in Gout Clinical Trials
Abstract Number: 2221

Racial Differences in Cardiovascular Events and Adverse Pregnancy Outcomes Among Pregnant Individuals With Systemic Lupus Erythematosus
Abstract Number: 1075

Racial Differences in Management and Clinical Outcomes of Giant-Cell Arteritis: A Real-World Propensity-Matched Study
Abstract Number: 1076

Racial Differences in Real-World Use of Urate-Lowering and Adjunctive Therapies for Gout: A 10-Year Propensity-Matched Cohort Study
Abstract Number: 1074

Racial Disparities in Cardiovascular, Ocular, and Treatment Outcomes in US Patients with Behçet’s Disease: A Propensity-Matched Real-World Analysis
Abstract Number: 2024

Racial Disparities in Outcomes Among Patients With Neuromyelitis Optica: A Global Population-Based Study
Abstract Number: 2241

RADAR: A Deep Learning Pipeline for Automated Scoring of Joint Damage in Rheumatoid Arthritis Radiographs
Abstract Number: 2314

Radiographic and Ultrasonographic Assessments of Sesamoid Index in Patients with Psoriatic Arthritis
Abstract Number: 0390

Radiographic Assessment in Juvenile Spondyloarthritis: Evaluating the axJSpA Criteria Using Radiographs Alone Versus MRI
Abstract Number: 0771

Radiographic Knee Osteoarthritis and Corticosteroid Injection Use: The Moderating Role of Physical Activity
Abstract Number: 0524

Radiographic progression in sacroiliac joints in five years follow up in non-radiographic axial spondyloarthritis patients and the predictive factors
Abstract Number: 1431

Radiographic Sacroiliitis in Psoriatic Arthritis: Clinical, Laboratory, and Spinal Radiographic Correlates in an Indian Cohort
Abstract Number: 0552

Radiographic Sacroiliitis Progression in Psoriatic Arthritis
Abstract Number: 0928

Radiolabelled anti-citrullinated histone antibody CIT-013 as a tool to visualize NET rich inflamed joints in a collagen induced arthritic mouse model
Abstract Number: 2081

Radiologic surveillance in the Phase II RCT of LEVI-04, a novel neurotrophin-3 inhibitor, in people with knee osteoarthritis: exclusions at screening
Abstract Number: 2160

RadRheum: Improving Resident and Medical Student Musculoskeletal Radiology Interpretation Skills Utilizing an Interactive Module
Abstract Number: 0261

Randomized Confirmatory Basket Trial: Performance Evaluation of a Simulated Application Example in Rare Disease Using Real World Data
Abstract Number: LB12

Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial of an Innovative Intra-Articular Apoptotic Cell Therapy in Knee Osteoarthritis (OA): 3-Month Positive Outcomes and Identification of Responder Population (NCT06233474)
Abstract Number: 2675

RANTES and CXCL10 as Potential Tear-Based Biomarkers Associated with Ocular Damage in Pediatric Chronic Anterior Uveitis
Abstract Number: 1534

Rapid Oral Glucocorticoid Discontinuation or Dose Reduction Among US Patients with SLE Receiving Belimumab in a Real-World Setting
Abstract Number: 2571

Rare Clinically Significant Methotrexate Toxicity Despite Frequent Laboratory Abnormalities: A Population-Based Study of Methotrexate Monitoring
Abstract Number: 2666

Rare TNFAIP3 Hypomorphic Variants are a Massively Underestimated Driver of Human Autoinflammatory Disease
Abstract Number: 1921

Re-escalation of Treatment in Older Adults with Rheumatoid Arthritis After Anti-TNF Therapy De-escalation
Abstract Number: 0533

Reactive Arthritis Transcriptomics: Enriched Enterobacteriaceae-related Pathways in Synovial Fluid and in Blood is Associated with Drug-free Remission
Abstract Number: 1926

Real World Rate of Efficacy of Adalimumab Biosimilars Following a Mandated Switch in an Academic Medical Center
Abstract Number: 0648

Real World Comparative Use of Anifrolumab in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A Multicenter Cohort Study
Abstract Number: 1348

Real World Evaluation on the Effectiveness of Baricitinib or Other Treatments in Patients With Rheumatoid Arthritis: Data from the European and Non-European Cohorts of the RA-BE-REAL Study
Abstract Number: 0554

Real world experience with generic Tofacitinib in Axial Spondyloarthritis from North India
Abstract Number: 0738

Real World Steroid Burden, Treatment Patterns, and Rheumatologists’ Perceptions on Advanced Therapy in Giant Cell Arteritis
Abstract Number: 1401

Real World Treatment Patterns and Health Care Resource Use in Patients With Newly Diagnosed Sjögren’s Disease (SjD) in the United States
Abstract Number: 2139

Real-Life Treatment Strategies for Refractory Still’s Disease: Results from a Worldwide Survey, the METAPHOR Project
Abstract Number: 1205

Real-time MRI for assessment of swallowing impairment in inclusion body myositis and oculopharyngeal muscular dystrophy.
Abstract Number: 0792

Real-World Assessment of Glucocorticoid-Induced Skin Toxicity in Individuals with Rheumatic Diseases
Abstract Number: 0726

Real-World Avacopan Use in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Insights from United States Claims Data on Outcomes and Adherence
Abstract Number: 2364

Real-World Characteristics and Treatment Patterns of Difficult-to-Treat Psoriatic Arthritis
Abstract Number: 0513

Real-world Clinical and Diagnostic Features of Patients with Isolated Anti-SSB Antibodies Compared to Those with Combination Anti-SSA and Anti-SSB Antibodies
Abstract Number: 1600

Real-world clinical effectiveness of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis: a National multicenter study
Abstract Number: 2299

Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive interstitial lung disease associated with primary sjögren’s syndrome
Abstract Number: 1444

Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis
Abstract Number: 1453

Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors
Abstract Number: 0502

Real-World Comparative Safety of Tocilizumab and Sarilumab in Rheumatoid Arthritis: A Multi-Center Observational Study
Abstract Number: 2342

Real-World Effectiveness and Satisfaction in Biologic-Naïve Patients With Psoriatic Arthritis and Limited Joint Involvement Treated With Risankizumab in the United States and Europe
Abstract Number: 0661

Real-world Effectiveness and Usage of Voclosporin: Data from the Enlight-LN Registry
Abstract Number: 1629

Real-World Effectiveness of Interleukin-6 Receptor Inhibitors Compared to Methotrexate in Steroid-Refractory Frail Patients with Polymyalgia Rheumatica
Abstract Number: 0238

Real-World Effectiveness of Mepolizumab on Gastrointestinal Involvement in Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome: A Multicenter Retrospective Study
Abstract Number: 2367

Real-World Effectiveness of Risankizumab on Axial Symptoms in Biologic-Naïve Patients With Psoriatic Arthritis in the United States and Europe
Abstract Number: 0578

Real-world Effectiveness of Upadacitinib on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Core Domains for Patients with Psoriatic Arthritis: Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Abstract Number: 1358

Real-World Evidence for the Superiority of Subcutaneous Methotrexate in RA: A Comparative Observational Study with Ultrasonographic Assessment
Abstract Number: 2670

Real-World Experience of Anifrolumab in 24 Patients with Refractory Dermatomyositis: A Multicenter Retrospective Study.
Abstract Number: 0474

Real-World Experience of Janus Kinase Inhibitors; Retention and Factors Associated with Discontinuation
Abstract Number: 0429

Real-world experience of upadacitinib therapy in difficult-to-treat juvenile idiopathic arthritis: a case series of 24 patients
Abstract Number: 2151

Real-World Experience with IL-1 Blockade in Children with Undifferentiated Systemic Autoinflammatory Diseases (uSAIDs)
Abstract Number: 1038

Real-World Immunosuppressant Treatment Patterns in Lupus Nephritis: A Retrospective Claims Database Analysis in the United States
Abstract Number: 2616

Real-World Implication of Clinical Disease Activity Index (CDAI) Utilization on Treatment Decisions and Clinical Outcomes in Rheumatoid Arthritis
Abstract Number: 2554

Real-World Observations on Symptom Response and Tolerability of Intravenous Immunoglobulin in Patients with Inflammatory Myopathies through a Nurse-Led Outcomes Monitoring Program in a Home Infusion Setting
Abstract Number: 2369

Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Interleukin-17A Inhibitors
Abstract Number: 1165

Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Tumor Necrosis Factor Inhibitors
Abstract Number: 1550

Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program
Abstract Number: 2338

Real-World Outcomes of Combined Tofacitinib and TNF Inhibitor Therapy in Refractory Inflammatory Arthritis: A Tertiary Care Experience from India
Abstract Number: 1457

Real-world Patient Trajectories in Psoriasis and Psoriatic Arthritis: a Retrospective Study
Abstract Number: 0369

Real-World Persistence of Janus Kinase Inhibitors in Biologic-Experienced Patients with Rheumatoid Arthritis
Abstract Number: 1586

Real-World Safety and Efficacy of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched EUSTAR Study
Abstract Number: 0201

Real-World study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase Inhibitors in comparison with healthy individuals
Abstract Number: 0572

Real-World Treat-to-Target Strategy in Psoriatic Arthritis: 48-week Results from the MONITOR-PsA Cohort
Abstract Number: 1924

Real-World Treatment Patterns of Patients with Systemic Autoimmune Rheumatic Disease-associated Interstitial Lung Disease After Progression in The United States
Abstract Number: 1282

Real-world use of belimumab in childhood-onset SLE in Spain: cross-sectional analysis from a multicenter study (JULES registry)
Abstract Number: 2038

Real-World Use of Dual Targeted Therapy in Rheumatic Disease: A Single-Center Case Series
Abstract Number: 0400

Recent Antibiotic Exposure and Response to Treatment of Juvenile Idiopathic Arthritis
Abstract Number: 1021

Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases
Abstract Number: 2196

Recognition and Treatment of Idiopathic Granulomatous Mastitis: A Case Series
Abstract Number: 1667

Recurrent or Incident Pericarditis With Concurrent Autoimmune Disease: Stable Control With Rilonacept Interleukin-1 Pathway Inhibition
Abstract Number: 1430

Redefining BASDAI cut-offs: implications for patients’ eligibility for initiating biologic disease-modifying antirheumatic treatment in axial spondyloarthritis
Abstract Number: 1773

Redefining disease activity assessment in IgG4-Related Disease: The role of classical and novel biomarkers
Abstract Number: 0772

Redefining When to Biopsy the Kidney in Patients with SLE
Abstract Number: 1712

Reduced Cardiometabolic Burden and Inflammation in Patients with Psoriatic Arthritis Cared for in a Multi-Disciplinary, Combined Psoriasis-Psoriatic Arthritis Center
Abstract Number: 0931

Reduced mitophagy in salivary glands of Sjögren’s disease patients is associated with mitochondrial structural damage
Abstract Number: 2319

Reducing selection bias while maintaining precision through an integrated analysis: 2-year longitudinal analysis of imaging outcomes in the SPondyloArthritis Caught Early cohort
Abstract Number: 2442

Reduction in Extrafollicular B Cell Responses in SLE Patients after CAR T Cell Therapy
Abstract Number: 1998

Reduction in Tophi Observed in Patients with Uncontrolled Gout Treated with NASP: Results from Phase 3 DISSOLVE Studies
Abstract Number: 1015

Refining Administrative Algorithms For Accurate Identification of Patients with Systemic Sclerosis In Trinetx Research Network
Abstract Number: 1899

Regional Variability in SLE Damage Accumulation by Disease Activity Across the Lupus Federated Data Network (LupusNet)
Abstract Number: 1955

Regional variations in the relationship between pericoronary fat enhancement and atherosclerosis may reflect differences in local vascular inflammation in rheumatoid arthritis
Abstract Number: 0084

Regulation of the same chemokine gene transcription by different histone lysine methyltransferases, MLL1 and MLL3, in rheumatoid arthritis synovial fibroblasts
Abstract Number: 0587

Regulatory Role of IL17 F in the Pannus Formation of Psoriatic Arthritis: A Comparative Study with IL-17A
Abstract Number: 0892

Relapse and Immune Dysregulation in Giant Cell Arteritis Are Linked to Mosaic Loss of the Y Chromosome
Abstract Number: 1212

Relapse in Idiopathic Inflammatory Myopathies: insights from extended MyoCite and Italian Consortia
Abstract Number: 0762

Relapse rate, predictors of relapses and impact of introduction of interleukin-6-receptor inhibition on relapse rate in GCA- Data from the large REATS cohort from six vasculitis centers
Abstract Number: 1949

Relapsing Polychondritis: Mimicking Asthma while Airways get Damaged
Abstract Number: 1247

Relation of Measures of Pain Sensitization to Widespread Pain
Abstract Number: 1329

Relationship Between Circulating Bacterial Small RNAs, Methotrexate Response, and Microbiome in New Onset Rheumatoid Arthritis
Abstract Number: 2557

Relationship Between Sleep Quality and Psychiatric Symptoms in Autoimmune Rheumatic Diseases
Abstract Number: 1968

Relationship between ultrasonographic and elastographic findings of the median nerve and disease activity and hand function in patients with rheumatoid arthritis
Abstract Number: 1704

Relationships between Neighborhood Disadvantage, Cumulative Social Disadvantage, and JIA Outcomes: A CARRA Registry Study
Abstract Number: 1242

Relax the Body: Dual-Agent Nighttime Therapy for Fibromyalgia: Symptom Reduction Using Tricyclic Antidepressants and Muscle Relaxants
Abstract Number: 2435

Relevant Symptoms and Signs of Active Discoid and/or Subacute Cutaneous Lupus Erythematosus Among Participants in a Phase 2 Clinical Trial: Patient-Embedded Qualitative Interviews
Abstract Number: 2124

Reliability and Validation of the Physician’s Global Assessment of Lung Disease (PGALD) in Systemic Juvenile Idiopathic Arthritis -Associated Lung Disease (SJIA-LD)
Abstract Number: 0802

Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study
Abstract Number: 1215

Remission Rates and Predictors in Idiopathic Inflammatory Myopathy Subtypes: Insights from a Single-Center Cohort
Abstract Number: 1469

Remission, Low Level Disease Activity State (LLDAS) and Relapse in Patients With Early-Onset, Adult-Onset and Late-Onset Systemic Lupus Erythematosus
Abstract Number: 2479

REMS technology 5-y Imminent Fracture Risk in Systemic Sclerosis.
Abstract Number: 1147

Renal Manifestations in VEXAS Syndrome: A Systematic Review of Clinical Features, Pathology, and Outcomes
Abstract Number: 2043

Renal Outcomes of Long-term Canakinumab in Patients with Adult Familial Mediterranean Fever (FMF) and Biopsy-Confirmed AA Amyloidosis
Abstract Number: 1379

Renal tubular acidosis in Sjögren’s disease and non-Sjögren’s sicca in an Oklahoma cohort
Abstract Number: 2381

Renal Tubular Complement C9 Deposition is Linked to Tubulointerstitial Fibrosis and Progression to Chronic Kidney Disease in Lupus Nephritis
Abstract Number: 0666

Reported Adverse Events Associated With Systemic Lupus Erythematosus (SLE) Treatment: Insights From the FDA Adverse Event Reporting System (FAERS) 2023
Abstract Number: 2507

Reporting of infectious and hepatic adverse events with avacopan: insights from the World Health Organization pharmacovigilance database (VigiBase)
Abstract Number: 0056

Repository Corticotropin Injection Reduces Inflammation and Bone Turnover Markers in the Murine CIA Model
Abstract Number: 1398

Reproductive Challenges and Cardiovascular Risks in Sjögren’s Syndrome and Systemic Sclerosis: A Meta-Analysis of Fertility, Pregnancy Outcomes, and Maternal Cardiac Health
Abstract Number: 0465

Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women
Abstract Number: 2669

RESET-Myositis: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Idiopathic Inflammatory Myopathies
Abstract Number: 2468

RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis
Abstract Number: 1563

RESET-SSc: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Systemic Sclerosis
Abstract Number: 0940

Resident Macrophages Localize Near Fibroblasts and Drive Reprogramming in Lupus Nephritis Through Direct and Soluble Signaling
Abstract Number: 0995

Resident Memory T Cells Stimulate Pathogenic Activity in Fibroblast-like Synoviocytes
Abstract Number: 2480

Respiratory Muscle Weakness in a Systemic Sclerosis Cohort
Abstract Number: 2098

Responder Phenotype Analysis for Intra-Articular Injections: Secondary Analysis from a Large Multi-Site Crossover Clinical Trial
Abstract Number: 1286

Response to Hydroxychloroquine in Immune Thrombocytopenia in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 1854

Resting-State Functional Magnetic Resonance Imaging Analysis Revealed Altered Functional Connectivity Associated with Fatigue in Systemic Lupus Erythematosus
Abstract Number: 1413

Restless Legs Syndrome in Patients with Psoriatic Arthritis: Association with Inflammatory, Clinical Parameters, and Comorbidities
Abstract Number: 2072

Results of an Integrated Program for Early Cancer Detection in Idiopathic Inflammatory Myopathies
Abstract Number: 2624

Results of Large Multi-Site Pragmatic Clinical Trial Comparing Corticosteroids or Blinded Lidocaine-only Injections in Treating Osteoarthritis of the Knee
Abstract Number: 0918

Retention of variant forms of TNFR1 in the Golgi induces stress responses and monocyte activation in systemic Juvenile Idiopathic Arthritis (sJIA)
Abstract Number: 1033

Rethinking ANA in Rheumatoid Arthritis: ICAP Pattern Insights from a Large-Scale Taiwanese Cohort
Abstract Number: 1474

Rethinking Heart Risk Prediction for Lupus Patients
Abstract Number: 0961

Retinoic acid-related orphan receptor-α: A novel upstream regulator of Hippo signaling and potential therapeutic target in fibrosis
Abstract Number: 1313

Retrospective Analysis of Factors Associated With Fracture in 2855 Patients With Rheumatoid Arthritis, Stratified by Steroid Use
Abstract Number: 0667

Retrospective Chart Audit Reveals Gaps in Steroid Tapering and Use of ACR Guideline-Recommended Regimens in LN
Abstract Number: 0430

Retrospective evaluation of the clinical impact of democgraphic , serological , clinical , radiological parameters and treatment modalities in patients with RA-ILD
Abstract Number: 1954

Revolutionizing Microvascular Screening: AI-Powered Dermatoscopy for Efficient Nailfold Capillary Evaluation
Abstract Number: 2182

Rheum for Improvement: A Needs Assessment Survey for an Internal Medicine Resident Curriculum
Abstract Number: 2150

Rheum to Grow:An Approach Towards Human Centered Design through a Qualitative Analysis on the Transition from Pediatric to Adult Rheumatology
Abstract Number: 0825

Rheum2Learn: A Randomized Trial of Virtual vs Text-Based Rheumatology Modules
Abstract Number: 0830

Rheum2Listen: Leveraging Podcasts to Teach Rheumatology to Internal Medical Residents
Abstract Number: 2167

Rheum4Games: A Game-Based Rheumatology Board Review for Internal Medicine Residents
Abstract Number: 0197

Rheumatoid arthritis (RA) patients who screen positive for anxiety, depression, and/or fibromyalgia are more likely to report problems with sleeping, memory, and/or social activities than to have an abnormal rheumatoid factor or ACPA
Abstract Number: 1880

Rheumatoid Arthritis Mortality in the U.S. (1999–2020): A Decline in Rates, But Not in Disparities
Abstract Number: 0147

Rheumatoid Arthritis prevalence estimation in France using care pathways in the National Health Data System: opportunities and limitations – PREST study
Abstract Number: 0170

Rheumatoid arthritis, serologic status and risk of heart failure: A national cohort study
Abstract Number: 1692

Rheumatoid factor is associated with increased gut permeability and migration of B cells to the joint via CXCR3 in rheumatoid arthritis
Abstract Number: 0074

Rheumatoid Factors (RFs) in RA Patient Sera Do Not Bind To Fc-Free Certolizumab Pegol, But Do Bind To Fc-Containing Anti-TNF-α Biological DMARDs, Driving Immune Complex Formation and Cellular Clearance
Abstract Number: 2149

Rheumatology Transitions of Care: Patient Stability and Follow-Up at a Single Center
Abstract Number: 0461

Right Diagnoses For the Wrong Reasons: Limitations of Current Large-Language Model based Agentic Frameworks for Screening of Rheumatoid Arthritis
Abstract Number: 1037

Risk Factor Identification and Dynamic Individualized Prediction of Muscle Involvement in Systemic Sclerosis
Abstract Number: 0161

Risk Factors and Clinical Predictors of Lung Cancer in Systemic Sclerosis: A Matched Case-Control Study from a Michigan Cohort
Abstract Number: 1467

Risk Factors Associated with Chronic Kidney Disease and End-Stage Kidney Disease in Patients with Newly Diagnosed Lupus Nephritis
Abstract Number: 0459

Risk Factors for Acute Exacerbation in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease
Abstract Number: 0402

Risk Factors for Anti-Adalimumab Antibody Development in Pediatric Patients Using Adalimumab for Rheumatic Disease and Associated Conditions
Abstract Number: 0142

Risk Factors for Antiphospholipid Syndrome-associated Nephropathy: A Retrospective Cohort Analysis
Abstract Number: 0203

Risk Factors for Cytomegalovirus Infection in Patients Receiving Prolonged High-Dose Corticosteroids for Rheumatic Diseases: A Retrospective Cohort Study
Abstract Number: 2232

Risk factors for hospitalizations in a large, contemporary rheumatoid arthritis patient cohort
Abstract Number: 1582

Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)
Abstract Number: 0621

Risk Factors for Pulmonary Manifestations in GLADEL 2.0, a Systemic Lupus Erythematosus Latin American Cohort
Abstract Number: 1733

Risk factors for the development of immune checkpoint inhibitor-related adverse events, including rheumatology-related presentations
Abstract Number: 2627

Risk of Adverse Pregnancy Outcomes in Individuals with Rheumatic Diseases Using Prenatal Antirheumatic Drugs: a Population-Based Cohort Study
Abstract Number: 2343

Risk of Arrhythmias Following IL-17 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Abstract Number: 0479

Risk of Arrhythmias Following IL-6 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Abstract Number: 1194

Risk of Calcinosis with Proton Pump Inhibitor Use in Adult Dermatomyositis and Systemic Sclerosis
Abstract Number: 1993

Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout
Abstract Number: 0818

Risk of Cardiovascular Events is Higher in Pregabalin Users Versus Duloxetine: A Cohort Study Among Veterans with Chronic Musculoskeletal Pain
Abstract Number: 0724

Risk of Drug Induced Liver Injury with Use of Avacopan in ANCA Vasculitis – Results from Real-World Data
Abstract Number: 0168

Risk of hospitalization in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
Abstract Number: 2658

Risk of Immune-Mediated Inflammatory Diseases and Other Safety Outcomes in Patients with T2DM and Obesity Initiating GLP-1 RA: A Propensity Score-Matched Multi-center Study using the TriNetX Global Network
Abstract Number: 1183

Risk of Inflammatory Bowel Disease in Psoriatic Arthritis Patients Treated with IL-17 Inhibitors
Abstract Number: 0837

Risk of New Proteinuria in Next Ten Years in SLE
Abstract Number: 1656

Risk of Serious Infection associated with non-TNF biologic initiation after Anti-TNF Use in Older Adults with Rheumatoid Arthritis
Abstract Number: 1747

Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
Abstract Number: 0884

Risk Score for Early Mortality to stratify for Intensive SSc Therapy
Abstract Number: 2118

Risks of Fracture in Current and Previous Anticonvulsant Users, An Observational Study
Abstract Number: 2448

Rituximab as the first line treatment in newly diagnosed systemic lupus erythematosus
Abstract Number: 1093

Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Abstract Number: 0135

Rituximab in Antiphospholipid Syndrome: aPL Titer Decline and Clinical Outcomes
Abstract Number: 2524

Rituximab in the Treatment of Susac Syndrome: Single Center Descriptive Study with a Large Susac Cohort
Abstract Number: 1203

Rituximab in Treatment Refractory vs Treatment Naive Anti-Signal Recognition Particle (SRP) Myositis – A Case Series
Abstract Number: 1525

Rituximab super-responders: characteristics of patients with more than 3 years response to a single cycle of treatment
Abstract Number: 1759

Role of a pathogenic bacterial factor produced by a human gut pathobiont in inducing platelet activation and thrombo-inflammation.
Abstract Number: 0107

Role of Achilles Elastography in Differentiating Patients with Early Psoriatic Arthritis
Abstract Number: 1857

Role of autoantigen-specific reactivity in the pathogenesis of murine interstitial lung disease model with anti-MDA5 antibody mouse model
Abstract Number: 2592

Romosozumab and Denosumab Combination Therapy in Postmenopausal Osteoporosis
Abstract Number: 2116

Romosozumab in Multiple Myeloma Patients at High Risk of Fracture
Abstract Number: 0341

Romosozumab in patients with Osteoporosis: Safety and Efficacy analysis in Clinical Practice
Abstract Number: LB19

Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Abstract Number: LB09

Rotation or Change of Biologic After TNF blocker treatment failure for axial Spondyloarthritis
Abstract Number: 0765

Rural Access to Physical Therapy for Osteoarthritis Rehabilitation (RAPTOR): A Pilot Feasibility Study
Abstract Number: 2143

Ruxolitinib for Refractory sJIA/AOSD: A Single Center Case Series